Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation

NCT02711202 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

20

Enrollment

OTHER_GOV

Sponsor class

Conditions

Kidney Transplantation

Interventions

DRUG: MabCampath,
DRUG: Remicade
DRUG: Sirolimus
DRUG: Tacrolimus

Sponsor

Institute for Clinical and Experimental Medicine

Collaborators

[object Object]
[object Object]